These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 30734249)

  • 1. Antagonistic effect between tigecycline and meropenem: successful management of KPC-producing Klebsiella pneumoniae infection.
    Bi S; Yao X; Huang C; Zheng X; Xuan T; Sheng J; Xu K; Zheng B; Yang Q
    Infection; 2019 Jun; 47(3):497-500. PubMed ID: 30734249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative serum bactericidal activity of meropenem-based combination regimens against extended-spectrum beta-lactamase and KPC-producing Klebsiella pneumoniae.
    Gaibani P; Lombardo D; Bartoletti M; Ambretti S; Campoli C; Giannella M; Tedeschi S; Conti M; Mancini R; Landini MP; Re MC; Viale P; Lewis RE
    Eur J Clin Microbiol Infect Dis; 2019 Oct; 38(10):1925-1931. PubMed ID: 31278562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Donor-derived Carbapenem-resistant Klebsiella pneumoniae Infection after Renal Transplantation with Tigecycline and Extended-infusion Meropenem.
    Wang ZQ; Guo ZL; Feng H; Fu C; Zhao GY; Ma K; Zhu L; Chen G
    Curr Med Sci; 2021 Aug; 41(4):770-776. PubMed ID: 34403102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tigecycline resistance caused by rpsJ evolution in a 59-year-old male patient infected with KPC-producing Klebsiella pneumoniae during tigecycline treatment.
    He F; Shi Q; Fu Y; Xu J; Yu Y; Du X
    Infect Genet Evol; 2018 Dec; 66():188-191. PubMed ID: 30268919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of
    Zhang W; Guo Y; Yang Y; Dong D; Zheng Y; Zhu D; Hu F
    Microb Drug Resist; 2020 Mar; 26(3):204-210. PubMed ID: 31553260
    [No Abstract]   [Full Text] [Related]  

  • 6. Tigecycline susceptibility and the role of efflux pumps in tigecycline resistance in KPC-producing Klebsiella pneumoniae.
    He F; Fu Y; Chen Q; Ruan Z; Hua X; Zhou H; Yu Y
    PLoS One; 2015; 10(3):e0119064. PubMed ID: 25734903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae.
    Sun D; Rubio-Aparicio D; Nelson K; Dudley MN; Lomovskaya O
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 29038260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of synergism between colistin, fosfomycin and tigecycline against extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates or with carbapenem resistance.
    Ku YH; Chen CC; Lee MF; Chuang YC; Tang HJ; Yu WL
    J Microbiol Immunol Infect; 2017 Dec; 50(6):931-939. PubMed ID: 28716360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of meropenem heteroresistance in Klebsiella pneumoniae carbapenemase (KPC)-producing clinical isolates of K. pneumoniae.
    Pournaras S; Kristo I; Vrioni G; Ikonomidis A; Poulou A; Petropoulou D; Tsakris A
    J Clin Microbiol; 2010 Jul; 48(7):2601-4. PubMed ID: 20504985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors, outcomes and genotypes of carbapenem-nonsusceptible Klebsiella pneumoniae bloodstream infection: a three-year retrospective study in a large tertiary hospital in Northern China.
    Zheng SH; Cao SJ; Xu H; Feng D; Wan LP; Wang GJ; Xiao XG
    Infect Dis (Lond); 2018 Jun; 50(6):443-451. PubMed ID: 29303020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of fosfomycin in combination with imipenem, meropenem, colistin and tigecycline against OXA 48-positive Klebsiella pneumoniae strains.
    Evren E; Azap OK; Çolakoğlu Ş; Arslan H
    Diagn Microbiol Infect Dis; 2013 Jul; 76(3):335-8. PubMed ID: 23726147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of tigecycline alone or in combination for experimental infections by KPC carbapenemase-producing Klebsiella pneumoniae.
    Fergadaki S; Renieris G; Machairas N; Sabracos L; Droggiti DI; Misiakos E; Giamarellos-Bourboulis EJ
    Int J Antimicrob Agents; 2021 Sep; 58(3):106384. PubMed ID: 34161789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro evaluation of different antimicrobial combinations against carbapenemase-producing Klebsiella pneumoniae: the activity of the double-carbapenem regimen is related to meropenem MIC value.
    Oliva A; Scorzolini L; Cipolla A; Mascellino MT; Cancelli F; Castaldi D; D'Abramo A; D'Agostino C; Russo G; Ciardi MR; Mastroianni CM; Vullo V
    J Antimicrob Chemother; 2017 Jul; 72(7):1981-1984. PubMed ID: 28369424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay.
    Pournaras S; Vrioni G; Neou E; Dendrinos J; Dimitroulia E; Poulou A; Tsakris A
    Int J Antimicrob Agents; 2011 Mar; 37(3):244-7. PubMed ID: 21236643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is meropenem MIC increase against KPC-producing Klebsiella pneumoniae correlated with increased resistance rates against other antimicrobials with Gram-negative activity?
    Cojutti P; Sartor A; Bassetti M; Scarparo C; Pea F
    J Glob Antimicrob Resist; 2018 Sep; 14():238-241. PubMed ID: 29775786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
    Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
    Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of Ceftazidime-Avibactam Alone and in Combination with Ertapenem, Fosfomycin, and Tigecycline Against Carbapenemase-Producing
    Ojdana D; Gutowska A; Sacha P; Majewski P; Wieczorek P; Tryniszewska E
    Microb Drug Resist; 2019 Nov; 25(9):1357-1364. PubMed ID: 31295055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacokinetics of High-Dose Continuous-Infusion Meropenem and Considerations for Use in the Treatment of Infections Due to KPC-Producing Klebsiella pneumoniae.
    Cojutti P; Sartor A; Righi E; Scarparo C; Bassetti M; Pea F
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28760900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence of a Fatal ST11-KL64 Tigecycline-Resistant Hypervirulent Klebsiella pneumoniae Clone Cocarrying
    Huang J; Yi M; Yuan Y; Xia P; Yang B; Liao J; Dang Z; Luo S; Xia Y
    Microbiol Spectr; 2022 Dec; 10(6):e0253922. PubMed ID: 36205391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence of tigecycline- and carbapenem-nonsusceptible Klebsiella pneumoniae ST11 clone in patients without exposure to tigecycline.
    Sheng ZK; Wang W; Guo Q; Xu X; Wang M; Yang Y; Wang M
    J Microbiol Immunol Infect; 2016 Dec; 49(6):962-968. PubMed ID: 26692183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.